SIL204 treatment may help immune system attack KRAS-driven tumors, research finds - exclusive...

Science and health | Aug 5, 2026, 12:01 PM

Research indicates that the SIL204 treatment may enable the immune system to attack KRAS-driven tumors.

The drug advanced into Phase 2/3 clinical evaluation at the end of July, with its first trial beginning at Tel Aviv Sourasky Medical Center.

PRO: see who's reacting and what you're missing. See the whole picture →